Day One Biopharmaceuticals Inc banner
D

Day One Biopharmaceuticals Inc
NASDAQ:DAWN

Watchlist Manager
Day One Biopharmaceuticals Inc
NASDAQ:DAWN
Watchlist
Price: 21.42 USD -0.09% Market Closed
Market Cap: $2.2B

Wall Street
Price Targets

DAWN Price Targets Summary
Day One Biopharmaceuticals Inc

Wall Street analysts forecast DAWN stock price to drop over the next 12 months.

According to Wall Street analysts, the average 1-year price target for DAWN is 21.17 USD with a low forecast of 17.17 USD and a high forecast of 22.58 USD.

Lowest
Price Target
17.17 USD
20% Downside
Average
Price Target
21.17 USD
1% Downside
Highest
Price Target
22.58 USD
5% Upside
Day One Biopharmaceuticals Inc Competitors:
Price Targets
SSRM
SSR Mining Inc
27% Upside
ESQ
Esquire Financial Holdings Inc
15% Upside
PTEN
Patterson-UTI Energy Inc
-10% Downside

Revenue
Forecast

N/A
Past Growth
37% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average
N/A
Past Growth
37% / Year
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

The compound annual growth rate of Day One Biopharmaceuticals Inc's revenue for the next 3 years is 37%.

Operating Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
1%
Average Beat

Net Income
Forecast

N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-23%
Average Miss
N/A
Past Growth
N/A
Estimated Growth
Estimates Accuracy
-23%
Average Miss
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is DAWN's stock price target?
Price Target
21.17 USD

According to Wall Street analysts, the average 1-year price target for DAWN is 21.17 USD with a low forecast of 17.17 USD and a high forecast of 22.58 USD.

What is Day One Biopharmaceuticals Inc's Revenue forecast?
Projected CAGR
37%

The compound annual growth rate of Day One Biopharmaceuticals Inc's revenue for the next 3 years is 37%.

Back to Top
Get AI-powered insights for any company or topic.
Open AI Assistant

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett